Abstract
Osteoporosis is a pathologic process characterized by low bone mass with skeletal fragility and an increased risk of fracture. It occurs due to an imbalance between bone resorption and formation. Although current antiresorptive therapy halts bone loss, it does not cure the condition as it also inhibits bone formation. Recent preclinical and clinical trials suggest that the inhibition of resorption by cathepsin K inhibitors increases bone formation. Cathepsin K is a papainlike cysteine protease with high potent collagenase activity and predominantly expressed in osteoclasts. While allowing demineralization, cathepsin K inhibitors suppress the degradation of type I collagen (the major organic matrix of bone) and thus enhancing bone formation. Many of these inhibitors have passed preclinical studies and are presently in clinical trials at different stages of advancement. This review explores the promising role of cathepsin K as a novel antiresorptive for the treatment of osteoporosis.
Keywords: Bone remodeling, bone resorption, bone turnover markers, cathepsin K, selective cathepsin K inhibitors, osteoporosis, osteoclast.
Current Drug Targets
Title:Cathepsin K Inhibitors: A Novel Target but Promising Approach in the Treatment of Osteoporosis
Volume: 14 Issue: 13
Author(s): Asadul Mazid Helali, Farhana Matin Iti and Isa Naina Mohamed
Affiliation:
Keywords: Bone remodeling, bone resorption, bone turnover markers, cathepsin K, selective cathepsin K inhibitors, osteoporosis, osteoclast.
Abstract: Osteoporosis is a pathologic process characterized by low bone mass with skeletal fragility and an increased risk of fracture. It occurs due to an imbalance between bone resorption and formation. Although current antiresorptive therapy halts bone loss, it does not cure the condition as it also inhibits bone formation. Recent preclinical and clinical trials suggest that the inhibition of resorption by cathepsin K inhibitors increases bone formation. Cathepsin K is a papainlike cysteine protease with high potent collagenase activity and predominantly expressed in osteoclasts. While allowing demineralization, cathepsin K inhibitors suppress the degradation of type I collagen (the major organic matrix of bone) and thus enhancing bone formation. Many of these inhibitors have passed preclinical studies and are presently in clinical trials at different stages of advancement. This review explores the promising role of cathepsin K as a novel antiresorptive for the treatment of osteoporosis.
Export Options
About this article
Cite this article as:
Helali Mazid Asadul, Iti Matin Farhana and Mohamed Naina Isa, Cathepsin K Inhibitors: A Novel Target but Promising Approach in the Treatment of Osteoporosis, Current Drug Targets 2013; 14 (13) . https://dx.doi.org/10.2174/13894501113149990202
DOI https://dx.doi.org/10.2174/13894501113149990202 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and Anticancer Properties of Methyl N1-(thien-4-yl)amidrazone- 3-carboxylates
Letters in Drug Design & Discovery Viral Elements Sense Tumorigenic Processes:Approaching Selective Cancer Therapy
Mini-Reviews in Medicinal Chemistry Preventive and Therapeutic Effects of the Retinoid X Receptor Agonist Bexarotene on Tumors
Current Drug Metabolism Effects of the Natural Isoflavonoid Genistein on Growth, Signaling Pathways and Gene Expression of Matrix Macromolecules by Breast Cancer Cells
Mini-Reviews in Medicinal Chemistry The Role of Metabolizing Enzymes and Transporters in Antiretroviral Therapy
Current Topics in Medicinal Chemistry Managing Expectations in the Transition to Proof of Concept Studies
Reviews on Recent Clinical Trials SNP Analysis Combined with Protein Structure Prediction Defines Structure- Functional Relationships in Cancer Related Cytochrome P450 Estrogen Metabolism
Current Medicinal Chemistry Patent Selections
Recent Patents on DNA & Gene Sequences Computational Analysis of Drug Resistance Network in Lung Adenocarcinoma
Anti-Cancer Agents in Medicinal Chemistry Meitner-Auger Electron Emitters for Targeted Radionuclide Therapy: Mercury-197m/g and Antimony-119
Current Radiopharmaceuticals Cross Talks Between Oncoprotein Signaling Networks and Tumor Suppressor p53 in Breast Cancer
Current Cancer Therapy Reviews Life and Death of Nerve Cells: Therapeutic Cytokine Signaling Pathways
Current Signal Transduction Therapy Multiclass Comparative Virtual Screening to Identify Novel Hsp90 Inhibitors: A Therapeutic Breast Cancer Drug Target
Current Topics in Medicinal Chemistry Molecular Pathways and Related Target Therapies in Liver Carcinoma
Current Pharmaceutical Design The Role of Insulin Receptor Isoforms and Hybrid Insulin/IGF-I Receptors in Human Cancer
Current Pharmaceutical Design Prolylcarboxypeptidase Gene Expression in the Heart and Kidney: Effects of Obesity and Diabetes
Cardiovascular & Hematological Agents in Medicinal Chemistry Novel Experimental Design for Steady-state Processes: A Systematic Bayesian Approach for Enzymes, Drug Transport, Receptor Binding, Continuous Culture and Cell Transport Kinetics
Medicinal Chemistry DNA Methylation: A Possible Target for Current and Future Studies on Cancer?
Epigenetic Diagnosis & Therapy (Discontinued) Inhibitor Binding Sites in the Protein Tyrosine Phosphatase SHP-2
Mini-Reviews in Medicinal Chemistry Hijacking the Hedgehog Pathway in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry